Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LB1908

Cell therapy (CAR-T) · Kills target cells, directed at Claudin 18.2 (CLDN18) · developed by Legend Biotech USA

Phase 1 Most advanced trial
LEGN Developer
1 Registered trials

What is LB1908?

LB1908 is an autologous T-cell therapy engineered to express a chimeric antigen receptor specific for Claudin 18.2, a tight junction protein expressed on a variety of tumor cells. The engineered cells recognize and selectively kill Claudin 18.2-expressing tumor cells and are being studied in gastric, gastroesophageal-junction, esophageal and pancreatic cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
Claudin 18.2 (CLDN18) (antigen)
Mechanism
Kills target cells, directed at Claudin 18.2 (CLDN18)
Therapy area
Oncology
Developer
Legend Biotech USA Inc (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05539430 Phase 1 Gastric Cancer Active not recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Esophageal CancerGastric CancerGastroesophageal-junction CancerPancreatic Cancer

Other drugs acting on CLDN18

More from Legend Biotech USA

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LB1908

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.